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Background: Percutaneous liver biopsy is one of the most important and widely used 
methods for diagnosing chronic liver diseases; however, controversies related to the po-
tential risk of complications and patient discomfort still exist. 
Objectives: The objective of this study was to evaluate the safety and success rate of blind 
percutaneous liver biopsy.
Patients and Methods: We conducted a retrospective analysis of 1412 blind percutaneous 
thick-needle liver biopsies performed during 1977–2000 at a single center on 1110 pa-
tients, using archived medical data of the center.
Results: The overall success rate of obtaining a liver sample with this method was 95.3%. 
Of all the samples assessed, 91.7% were determined to be fully representative for an evalu-
ation by the pathologist. Complications occurred in 259 procedures (18.3%). While no fa-
talities associated with liver biopsy were noted, 9 serious complications (0.64%) directly 
related to biopsies were reported. Pain was the most common complication (15.3%). Sig-
nificantly more complications (pain and vasovagal reactions) were reported in females 
(22.1%) than in males (16.1%) (P = 0.005). The rate of complications was significantly cor-
related with the stage of fibrosis (P = 0.027), i.e. the higher the fibrosis stage, the higher 
the complication rate. Previous surgical procedures involving the abdominal cavity or 
thorax influenced the effectiveness of liver biopsy (P = 0.017). Less operator experience 
was significantly associated with a higher rate of procedure failure (P = 0.002). Statistical 
significance of the relationship between individual operator efficiency and complica-
tion rate (P = 0.000) and that between individual operator efficiency and biopsy failure 
rate (P = 0.002) was observed. 
Conclusions: Blind percutaneous liver biopsy is a safe and effective invasive procedure, 
despite the fact that noninvasive fibrosis assessment methods are currently widely avail-
able and used instead of histological evaluation. Complications risk and failure rate are 
low if indications and contraindications are considered carefully and the biopsy is per-
formed by a skilled and experienced operator. Certain groups of patients may benefit 
from an image-guided procedure to improve its effectiveness.
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 Implication for health policy/practice/research/medical education:
The paper summarizes the long-term clinical experience of single center in blind percutaneous liver biopsy with the large num-
ber of procedures performed. It indicates some important factors influencing the safety and effectiveness of the liver biopsy. This 
article is important for all clinicians who qualify patients to the liver biopsy and perform them. It may help to convince patients, 
who are afraid of the procedure, about its safety.
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1. Background
Percutaneous liver biopsy is one of the most impor-
tant and widely used methods for diagnosing chronic 
liver diseases. Indications for liver biopsy have evolved 
with the development of new molecular and serologic 
tests for the detection of liver diseases. In recent years, 
noninvasive techniques for the assessment of fibrosis 
have  been  developed  and  widely  used.  However,  only 
histological examination provides detailed information 
regarding elements of liver histopathology, including 
identification of particular types of inflammatory cells 
in infiltrates, storage of pathological substances (i.e. 
iron, copper), lesions in transplanted organs. Similar to 
other invasive procedures, a potential risk of complica-
tions,  including  death,  is  associated  with  liver  biopsy. 
The mortality rate, mainly because of hemorrhagic com-
plications, varies from 0% to 0.33% depending on the co-
hort analyzed (1-5). Bleeding in the peritoneal cavity and 
biliary peritonitis following puncture of the gall bladder 
or large bile duct are the most serious complications. The 
most common complications include pain of varying se-
verity and vasovagal reactions. Intrahepatic or subscapu-
lar hematomas are also observed in some cases. Other 
rare complications include pneumothorax, bleeding in 
the pleural cavity, puncture of adjacent abdominal or-
gans, infection, and breaking of the biopsy needle (2, 6). 
Accuracy of histological evaluation is directly dependent 
on adequate tissue samples (7, 8). Currently, image-guid-
ed biopsies are widely used to maximize the effective-
ness of the procedure, although their superiority over 
blind biopsies in practice is controversial (9-12). Despite 
long-term  clinical  experience  and  established  indica-
tions and contraindications, the role of liver biopsy in 
the diagnosis and management of chronic liver diseases 
remains debatable. Controversies mainly involve the po-
tential risk of complications and discomfort to patients, 
particularly in terms of the availability of contemporary 
noninvasive diagnostic techniques. 
2. Objectives
An evaluation of the safety and success rate of blind 
percutaneous liver biopsy based on retrospective single-
center data is presented in this paper.
3. Patients and Methods 
We  performed  a  retrospective  analysis  of  archived 
medical data of patients with chronic liver diseases, on 
whom percutaneous thick-needle liver biopsy was per-
formed as part of a standard diagnostic algorithm. All 
patients were hospitalized in the Department of Infec-
tious Diseases, Liver Diseases and Acquired Immunode-
ficiencies  of  Wroclaw  Medical  University  from  1977  to 
2000. Data collected from archived medical documenta-
tion included age, sex, indication for liver biopsy, labora-
tory test results, complications and outcomes, success of 
procedures, results of histological evaluation of tissue 
samples, and name of the operator and his/her experi-
ence in performing biopsies. Assessment of procedure 
success and obtaining a representative sample was based 
on the opinion of the pathologist. All patients gave the 
informed consent for liver biopsy, recorded in medi-
cal documentation. As preparation for the procedure, 
blood  group  was  established,  and  coagulation  param-
eter assessment, blood morphology tests, chest X-ray, 
and abdominal ultrasound (ultrasound since 1985) were 
performed. Patients were fasting before the procedure. A 
transthoracic approach was routinely used, with the pa-
tient in the supine position. All biopsies were blind and 
performed using Menghini-type suction needles, initial-
ly with multiple-use devices and then using single-use 
ones starting 1997, i.e. Hepafix (B. Braun Melsungen AG, 
Germany) sets. Needle diameters ranged from 1.4 to 1.8 
mm. A 2% lidocaine solution was administered for local 
anesthesia. In some cases, intramuscular diazepam was 
administered as premedication. General anesthesia was 
used for biopsies of children under 14 years of age. All bi-
opsies were performed on hospitalized patients who re-
mained under observation for 1 day following the proce-
dure. All samples were evaluated by a single pathologist. 
The Scheuer scoring system was used for the assessment 
of fibrosis and inflammatory activity. A chi-square test 
was used for statistical analysis; P < 0.05 was considered 
statistically significant. Calculations were performed us-
ing licensed Statistica software, (Stat Soft Inc. Tulsa, OK, 
US), version 8.0.
4. Results
We  analyzed  data  from  1110  patients  on  whom  1412 
percutaneous  thick-needle  blind  liver  biopsies  were 
performed. Demographic characteristics of the study 
population are shown in Tabulation 1. The group includ-
ed 699 male and 411 female patients; 888 biopsies (62.9%) 
were  performed  on  males  and  524  (37.1%)  on  females. 
The median patient age was 37 years (range, 2–72 years). 
Indications for liver biopsy are presented in Tabulation 
2. Among 1412 liver biopsies performed, tissue samples 
Value
Total Patients, No. 1110
Total Liver Biopsies, No. 1412
Sex, No. (%)
Male
Female
699 (62.9) 
411 (37.1)
Caucasian, % 100
Age, y
Range
First biopsy, mean
All biopsies, mean
< 18 y, No.
Patients
Biopsies
2–72
35.9
36.2
105
130 
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were obtained from 1346 cases (95.3%), of which 1295 cas-
es (91.7%) were fully representative as assessed by the pa-
thologist. The obtained tissue samples did not allow for 
an accurate description of histological changes in 51 cas-
es (3.6%) because of the small number of portal tracts. Tis-
sue samples were not obtained from 66 (4.7%) biopsies. A 
total of 1153 (81.7%) biopsies were uncomplicated, while 
complications occurred in 259 biopsies (18.3%). No fatali-
ties associated with biopsies were noted. Nine serious 
complications  (0.64%),  directly  related  to  biopsy,  were 
reported as follows: 5 cases of hemorrhage to the peri-
toneal cavity, 2 cases of hemothorax of the right pleural 
cavity, and 2 cases of biliary peritonitis. Laparotomy was 
required in 3 cases (2 incidents of biliary peritonitis and 
1 massive hemorrhage to the peritoneal cavity). Drain-
age was needed for 1 hemothorax. In summary, a total of 
4 invasive interventions were needed, which accounted 
for 0.28% of all biopsies performed and 1.5% of all compli-
cated procedures. Clinical data from 9 patients with seri-
ous complications are summarized in Table 1. Pain at the 
site of puncture and/or right shoulder was the most com-
mon complication and accounted for 216 (15.3%) cases; of 
these, administration of analgesics was indicated in 88 
cases. Other reported complications included the follow-
ing: 29 (2.05%) cases of vasovagal reaction (syncope, re-
flex hypotension, transient bradycardia), 16 (1.13%) cases 
of bile duct puncture (without resulting in bile leak and 
biliary peritonitis), 10 (0.71%) cases of leukocytosis after 
biopsy (in 4 cases with clinical signs of infection, with 
antibiotic administration), and 3 other uncommon inci-
dents (2 episodes of anginal chest pain and 1 epileptic at-
tack). Symptoms and signs of all complications occurred 
during postbiopsy observations, not later than 24 hours 
after the procedure. In 76 biopsies of children, general 
anesthesia was used. There were no complications associ-
ated with anesthesia or any other serious complications 
in these cases. Significantly more complications were re-
ported in females (22.1%) than in males (16.1%) (P = 0.005). 
Pain (18.5% in women and 13.4% in men) and vasovagal 
Patients, No. (n = 1110)
Chronic hepatitis B 442
Chronic hepatitis C 302
Co-infection HBV/HCV 22
Liver cirrhosis (other than viral hepatitis) 34
Autoimmune hepatitis 22
Primary biliary cirrhosis 27
Abnormal liver tests 119
Alcoholic liver disease 43
NAFLD a 17
Toxic liver injury 18
Hyperbilirubinemia 42
Other 22
 
Tabulation 2. Indications for Liver Biopsy
a Abreviation: NAFLD;nonalcoholic fatty liver disease
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reactions (2.3% and 1.9%, respectively) accounted for this 
difference. The most serious complications were twice as 
common in males as in females, whereas the proportion 
of all biopsies performed on men compared with women 
was 1.7:1. Age did not influence the risk of complications. 
Biopsies were performed by 8 different operators who 
were specialists in infectious diseases. Their experience, 
which was evaluated in years of clinical practice, ranged 
from 0 to 19 years. Less experience (< 2 years) was sig-
nificantly associated with a higher biopsy failure rate (P 
= 0.002). Statistical significance of the relationship be-
tween individual operator efficiency and complication 
rate (P = 0.000) and that between individual operator ef-
ficiency and failure rate (P = 0.002) was observed. The re-
lationship of complications and failure rates according 
to operator and his/her experience is presented in Table 2.
A total of 393 patients had a history of at least 1 surgi-
cal procedure involving the abdominal cavity or tho-
rax (27.8% of all biopsies), which may have potentially 
changed the topography of organs in the abdominal 
cavity.  The  most  common  procedures  were  appendec-
tomy (190 cases) and cholecystectomy (105 cases). A total 
of 19 patients were operated for peritonitis for various 
reasons, and another nine for abdominal injuries. Table 
2 summarizes the significance of previous surgical pro-
cedures on the safety and effectiveness of liver biopsy. 
Among the unsuccessful biopsies, ten cases had a history 
of massive surgical intervention involving the abdomi-
nal cavity or organs adjacent to the liver, including five 
open cholecystectomies, two cases of purulent peritoni-
tis as a complication of appendicitis, one splenectomy 
after abdominal injury, one kidney transplantation, and 
one large bowel resection. Liver fibrosis was also con-
sidered a factor influencing the safety and effectiveness 
of biopsies. Since a large number of biopsies were per-
formed before the introduction of the scoring systems 
to the practice in the center, the presence or absence of 
fibrosis and the stage of fibrosis were assessed separately. 
The presence of fibrosis had no influence on the biopsy 
failure and complication rates. In 386 samples, the stage 
of fibrosis was established using the Scheuer scoring sys-
tem and no fibrosis was described in 546 samples. Failure 
rate did not depend on the stage of fibrosis; however, the 
complication rate was significantly higher with a higher 
stage of fibrosis, as depicted in Table 2. In cases with early 
or complete cirrhosis, 25.3% of procedures were compli-
cated, with 1 incident of hemorrhage in the peritoneal 
cavity.
5. Discussion
Knowledge related to the risk of complications in liver 
biopsy  is  based  on  several  large  analyses,  which  were 
performed mainly in the 1970s–1990s, cited by majority 
of papers concerning liver biopsies. Most studies were 
retrospective (10, 13-15), similar to the present study, and 
some were based on multicenter databases (2, 5, 16). Few 
studies reported detailed prospective observations (3, 11, 
17). The analyzed groups were heterogeneous in terms 
of indications, underlying conditions, methods, needles 
used, and guiding techniques. Established risk factors 
for serious complications include liver cirrhosis, malig-
nancy, advanced age, impaired coagulation, and number 
of passes (3, 18). The time period of the present study was 
comparable to those of the other large analyses, which 
provided the possibility of including biopsies performed 
Failures, No. (%) P value Complications, No. (%) P value
Operator a 0.000 0.000
A (n = 244)
B (n = 17)
C (n = 59)
D (n = 135)
E (n = 55)
F (n = 148)
G (n = 128)
H (n = 593)
11 (4.5)
4 (23.5)
9 (15.3)
10 (7.4)
3 (5.5)
8 (5.4)
5 (3.9)
5 (3.9)
76 (31.1)
2 (11.8)
4 (6.8)
35 (25.9)
8 (14.5)
27 (18.2)
7 (5.5)
95 (16.0)
Operator Experience, y a 0.002 0.126
< 1 (n = 73)
1–2 (n = 232)
3–5 (n = 318)
> 5 (n = 756)
5 (6.8)
21 (9.0)
17 (5.3)
23 (3.0)
9 (12.3)
36 (15.5)
54 (17.0)
155 (20.5)
Previous Surgical Procedures on Abdominal Cavity and Thorax b 0.017 0.187
Surgical procedures (n = 393)
Nonsurgical procedures (n = 1010)
27 (6.9)
39 (3.9)
81 (20.6)
177 (17.5)
Staging  0.027
0–1 (n = 769)
2–4 (n = 163)
-
-
131 (17.0)
41 (25.2)
Table 2. Complications and Failure Rates According to Different Options
a 33 biopsies were without data
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with older biopsy devices, similar to other papers. Biopsy 
indications  were  diverse  during  that  period;  however, 
in more recent years, the main indication was chronic 
viral hepatitis. The overall rate of complications in the 
analyzed group was low (18.3%) and the small number 
of serious complications (9–0.64%) observed was com-
parable to that of the other large cohorts (0.22–0.75%) 
(1, 2, 4, 11, 15, 16). No fatalities were reported, which may 
be attributable to the absence of the serious risk factors 
listed above in majority of patients and careful consider-
ation of indications and contraindications for the proce-
dure. Moreover, the needle used was the Menghini-type 
suction needle, which carries a smaller risk of bleeding 
compared with cutting needles such as the Tru-cut nee-
dle used widely in other cohorts (5, 17). The small num-
ber of serious complications did not allow for a detailed 
assessment of risk factors. More common reporting of 
pain and vasovagal reactions in women, similar to that 
described in other papers (11), might be partly because of 
underreporting of pain by men, or possibly as the result 
of a greater emotional reaction to the invasive procedure 
by women, observed by authors in clinical practice. Data 
concerning pain incidence are discordant and varying 
(range, 1.16–30%) in different reports (2, 5, 13, 19, 20). Sever-
ity of pain may be accurately evaluated only in prospec-
tive studies, based on pain scoring systems (21, 22). The 
incidence of pain, particularly in mild cases without the 
need for analgesic administration, obtained from medi-
cal documentation in retrospective analyses, is probably 
often underreported. Few studies analyzed in detail the 
factors  related  to  liver  biopsy  effectiveness;  they  were 
mainly concerned with the assessment of the effective-
ness of image-guided procedures compared to blind 
biopsies (10, 11). In the data presented here, all the biop-
sies were blind; therefore, a comparison of the present 
analysis with other analyses is impossible. The relatively 
high failure rate in the present analysis (4.7%) may partly 
be attributed to the use of the suction needle. Cutting 
needles used in a large proportion of other studies per-
mit the collection of larger tissue samples (23). Other au-
thors have reported failure rates of 1–2.2% (10, 17, 19, 24), al-
though Gilmore noted 5% of failures despite ultrasound 
guidance in majority of procedures (5). Although pre-
liminary and not a detailed observation, this study pres-
ents a unique finding of statistically significant higher 
failure rate of biopsies in patients with previous surgical 
procedures involving the thoracic or abdominal cavity. 
No other study has performed such analysis or reported 
this significance. One study discussed the variability of 
the anatomy and topography of the liver and adjacent or-
gans found in computed tomography scans. The authors 
concluded that this variability may potentially affect the 
safety and success rate of blind liver biopsies (25). Pre-
vious extensive surgical operations or massive inflam-
matory processes (i.e. peritonitis) may have a similar 
impact on abdominal organ topography, and this group 
of patients may certainly benefit from an image-guided 
procedure. Such a recommendation is also presented in 
the current guidelines of the American Association for 
the Study of Liver Disease for liver biopsies (6). Another 
interesting observation was the impact of operator expe-
rience and skill on the safety and success rate of liver bi-
opsy. In the present analysis, complication rates differed 
according to the skill of the operators, but not their ex-
perience, which suggests the important role of personal 
skill and precision as qualifications for performing the 
procedure compared to experience. The higher number 
of complications noted in procedures performed by ex-
perienced operators may also be due to the fact that they 
performed more technically difficult biopsies or biopsies 
on patients with risk factors.
Some authors reported similar observations indicating 
the role of clinical experience in the effectiveness of the 
procedure (5, 14), whereas others in a French multicenter 
analysis did not find any such relationship (11). Data con-
cerning the influence of operator experience on com-
plication rate are ambiguous. Cadranel and Froehlich 
reported a higher complication rate in procedures per-
formed by physicians during training compared with ex-
perienced operators (11, 16). On the contrary, Perrault and 
McGill did not observe this association (3, 17). There are 
several limitations in the interpretation of our findings. 
Our study was conducted over a relatively long time peri-
od, during which the available equipment had changed, 
namely with respect to the availability of ultrasound and 
single-use sets. The retrospective analysis of data may 
involve underreporting of minor symptoms, especially 
mild pain. A quantitative assessment of biopsy effective-
ness was impossible because the specimen length was 
not recorded. 
In conclusion, blind percutaneous liver biopsy is a safe 
and effective invasive procedure, provided that the indi-
cations, contraindications, and risk factors for compli-
cations and failure are considered carefully. Moreover, 
it is important that biopsies are performed by skilled 
and experienced operators. Certain groups of patients 
may benefit from image-guided procedures. The small 
complication rate established in the present study may 
convince patients who are afraid of undergoing liver bi-
opsy. Our results, confirming the safety of liver biopsy, 
are particularly significant for clinicians currently, when 
noninvasive fibrosis assessment methods (biochemical 
markers,  elastography)  are  more  widely  available  and 
used instead of histological evaluation. 
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